Pfizer launched Zirabev, Ruxience, Trazimera biosimilar in US
Posted on29 Jan 2020
TagsBevacizumab, Biosimilar, MAB, monoclonal antibody, pfizer, Rituximab, Ruxience, trastuzumab, Trazimera, Zirabev
Comments0
Pfizer has launched three biosimilars in the U.S. market. Pfizer has priced these biosimilars aggressively to get quick market share. Zirabev Biosimilar... Read More
USFDA approval of Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older
Roche announced that the US Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of... Read More
Case Study : Rituxan – A Brand which Pharma Industry reckon
Brand Name: Rituxan Company: Roche 2017 U.S. sales: $4.41 billion Disease: Blood cancers, rheumatoid arthritis Dosage form: Injection for Intravenous Use Rituxan (rituximab) is a... Read More
US FDA accepts Sandoz’s proposed biosimilar of rituximab for review
Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has... Read More
Intas’s Growth Driver : Biopharmaceuticals
Posted on23 Jan 2015
Tagsbiopharmaceuticals, Erykine®, Folisurge®, Intalfa®, Intas, Intas Biologics, Intass Biopharmaceuticals, Mabtas®, Neukine®, Pegasta®, Rituximab, Terifrac®
Comments0
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. Intas’s success and incessant growth... Read More
Torrent’s strategic alliance with Reliance Life Science for biosimilars
Torrent Pharmaceuticals Ltd , Ahmedabad based pharma company, has announced its entrance into an exclusive licensing agreement with Reliance Life Sciences for... Read More